hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06307431 id: V940-004 id: 2023-505177-32 type: OTHER domain: EU CT briefTitle: A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) overallStatus: RECRUITING date: 2024-04-10 date: 2028-01-08 date: 2032-06-08 date: 2024-03-12 date: 2024-04-29 name: Merck Sharp & Dohme LLC class: INDUSTRY name: ModernaTX, Inc. briefSummary: The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS. conditions: Renal Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 272 type: ESTIMATED name: V940 name: Pembrolizumab name: Placebo measure: Disease-Free Survival (DFS) measure: Overall Survival (OS) measure: Distant Metastasis-free survival (DMFS) measure: Percentage of Participants Who Experience an Adverse Event (AE) measure: Percentage of Participants Who Discontinue Study Treatment Due to an AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yale-New Haven Hospital-Yale Cancer Center ( Site 0102) status: RECRUITING city: New Haven state: Connecticut zip: 06510 country: United States name: Study Coordinator role: CONTACT phone: 203-785-5720 lat: 41.30815 lon: -72.92816 facility: Macquarie University-MQ Health Clinical Trials Unit ( Site 1502) status: RECRUITING city: Macquarie University state: New South Wales zip: 2109 country: Australia name: Study Coordinator role: CONTACT phone: +61 2 9812 3526 facility: CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 0008) status: RECRUITING city: Québec state: Quebec zip: G1R 2J6 country: Canada name: Study Coordinator role: CONTACT phone: 4185254444 lat: 46.81228 lon: -71.21454 facility: FALP-UIDO ( Site 1202) status: RECRUITING city: Santiago state: Region M. De Santiago zip: 7500921 country: Chile name: Study Coordinator role: CONTACT phone: 56224457254 lat: -33.45694 lon: -70.64827 facility: ONCOCENTRO APYS-ACEREY ( Site 1200) status: RECRUITING city: Viña del Mar state: Valparaiso zip: 2520598 country: Chile name: Study Coordinator role: CONTACT phone: +56992369820 lat: -33.02457 lon: -71.55183 hasResults: False
nctId: NCT06307418 id: Carer eSupport RCT briefTitle: Internet-based Support for Informal Caregivers of Patients With Head and Neck Cancer - Carer eSupport overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2025-10-31 date: 2025-10-31 date: 2024-03-12 date: 2024-04-01 name: Uppsala University class: OTHER name: The Swedish Research Council name: Swedish Cancer Society name: Umeå University name: Region Örebro County name: Sahlgrenska University Hospital, Sweden name: University Hospital, Umeå name: Uppsala University Hospital briefSummary: The aim of this randomized controlled trial is to investigate the effects of internet-based support (Carer eSupport) on preparedness for caregiving in informal caregivers of patients with head and neck cancer. The main question\[s\] it aims to answer are:
Informal caregivers in the intervention group will be compared to informal caregivers who receive standard care support regarding preparedness for caregiving, caregiver burden and wellbeing. conditions: Head and Neck Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Informal caregivers of patients with Head and neck cancer will be randomized to internet-based support or to support as usual. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 110 type: ESTIMATED name: Carer eSupport measure: The self-reported questionnaire Preparedness for caregiving scale measure: The self-reported questionnaire Caregiver Burden Scale measure: The self-reported questionnaire Depression Anxiety Stress Scale-21 (DASS21) measure: The self-reported health-related quality of life questionnaire RAND-36 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Örebro University Hospital city: Örebro state: Blekinge Län zip: 70185 country: Sweden lat: 59.27412 lon: 15.2066 facility: Uppsala university hospital city: Uppsala state: Uppsala Län zip: 75105 country: Sweden lat: 59.85882 lon: 17.63889 facility: Norrland University Hospital city: Umeå state: Västerbottens Län zip: 90737 country: Sweden lat: 63.82842 lon: 20.25972 facility: Sahlgrenska university hospital city: Göteborg state: Västra Götaland zip: 41345 country: Sweden lat: 57.70716 lon: 11.96679 hasResults: False
nctId: NCT06307405 id: WJP2023 briefTitle: The Value of mNGS in Diagnosis of Pulmonary Infection overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-04-20 date: 2025-09-30 date: 2024-03-12 date: 2024-03-12 name: Yunfeng Hou class: OTHER briefSummary: Retrospective analysis of clinical data from 50 hospital-admitted patients with suspected pulmonary infection (as judged by clinical manifestations and imaging findings) was performed on study participants who had collected two different samples of alveolar lavage fluid (BALF) and sputum and underwent metagenomic next generation sequencing (mNGS) and routine pathogen detection, respectively. The positive rate of pathogen detection and the consistency of pathogen detection results of the two detection methods were compared to evaluate the clinical manifestation and role of mNGS in pathogen diagnosis. conditions: Pulmonary Infection studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 50 type: ESTIMATED name: next generation sequencing measure: Etiological detection rates of two detection techniques measure: Consistency of detection results of two detection techniques sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06307379 id: EC 23022 briefTitle: Patient Reported Outcome and Experience Measures for Bronchoscopic Procedures acronym: BRONCHOPROEM overallStatus: RECRUITING date: 2024-02-13 date: 2025-12-30 date: 2025-12-30 date: 2024-03-12 date: 2024-03-12 name: Vitaz class: OTHER briefSummary: 'Patient-reported outcomes' (PROMS) and 'patient-reported experiences' (PREMS) are increasingly important parameters in evaluating and adjusting clinical procedures and strategies in healthcare.
Validated disease-specific PROMS related to bronchoscopic procedures are not available and examples in the medical literature are very scarce. conditions: Bronchial Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: no intervention measure: Procedure-related dyspnea scale (VAS) measure: Procedure-related pain scale (VAS) measure: Procedure related cough scale (VAS) measure: General patient satisfaction measure: Procedure-related complications: measure: Sedation-related complications measure: Diagnostic yield sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VITAZ status: RECRUITING city: Sint-Niklaas country: Belgium name: Jonas Yserbyt role: CONTACT email: jonas.yserbyt@vitaz.be lat: 51.16509 lon: 4.1437 hasResults: False
nctId: NCT06307366 id: ErasmusMC10365 briefTitle: Perceptions and Experiences of (Family Members of) People With Mental Illness About the Chance for Mental Illness in (Future) Children, and Needs for Care and Research acronym: PANDAcc overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-12 date: 2024-03-12 name: Erasmus Medical Center class: OTHER briefSummary: Despite consistent evidence that mental illness runs in families, intergenerational transmission of risk of mental illness is rarely considered in clinical practice. Neither preventive programs for children of parents with mental illness are usually implemented in care, nor supportive programs for parenting. Furthermore, parents with mental illness are not always aware of how their disorder may impact the well-being of their children. To date, the needs for counseling, care and research in parents with mental illness and family members of people with mental illness are unclear. Therefore, this prospective qualitative interview study aims to gain insights into the perceptions and experiences of (future) parents with mental illness, partners and family members of people with mental illness about risk for and resilience against mental illness in (future) children, as well as their needs for counseling, care and research. conditions: Mental Illness studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 10 type: ESTIMATED name: No intervention will be used measure: Themes around the topics (related to perceptions and experiences) explored. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus Medical Center city: Rotterdam state: Zuid-Holland zip: 3000CB country: Netherlands name: Lisanne AE van Houtum, PhD role: CONTACT phone: +31107037005 email: l.vanhoutum@erasmusmc.nl name: Hilmar H Bijma, MD, PhD role: CONTACT phone: +31107036109 email: h.bijma@erasmusmc.nl name: Hilmar H Bijma, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Neeltje EM van Haren, PhD role: SUB_INVESTIGATOR name: Lisanne AE van Houtum, PhD role: SUB_INVESTIGATOR name: Eline MP Poels, MD, PhD role: SUB_INVESTIGATOR lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06307353 id: Soh_Med_23_12_05MS briefTitle: Trends of Contraception Methods in Urban Medical Center in el_Balyana overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-10-01 date: 2025-03-01 date: 2024-03-12 date: 2024-03-12 name: Sohag University class: OTHER briefSummary: family planning is avital primary Health care intervention that saves lives of mothers and infants empowers women and support their choices regarding their health public life and additional education .In addition family planning is considered as a short term intervention to limit population growth and manage overpopulation problems.Globally the contraception prevalance rate an indicator for family planning programs continue to face challenges in developing countries. conditions: Contraception studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 385 type: ESTIMATED name: trends of contraception methods measure: number of married women in child bearing period attending the El_Balyana Medical Center using contraception methods . sex: FEMALE minimumAge: 15 Years maximumAge: 49 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06307340 id: 22-01058 briefTitle: Adaption of the STAIR-NT Trauma Intervention for Polysubstance Populations overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-10 date: 2024-03-12 date: 2024-04-04 name: NYU Langone Health class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors. conditions: Polysubstance Abuse conditions: Posttraumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: The data analyst is blinded to participant arm. whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT) name: Treatment as Usual measure: Proportion of Eligible Participants measure: Proportion of Eligible Participants who Enroll measure: Number of Intervention Sessions Completed measure: Clinician-Rated Feasibility of Intervention Measure (FIM) Score measure: Clinician-Rated Feasibility of Acceptability of Intervention Measure (AIM) Score measure: Number of Days of Co-Use of Cocaine and Illicit Opioids measure: Number of Substances Used based on ASI Self-Report measure: Number of Substances Used based on Urine Drug Screen measure: Number of Substances Used based on Chart Abstraction of Toxicology Results measure: PTSD Checklist for DSM-5 (PCL-5) Score measure: Negative Mood Regulation Scale Score measure: Inventory of Interpersonal Problems Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Florida State University city: Tallahassee state: Florida zip: 32306 country: United States name: Tanya Renn, PhD role: PRINCIPAL_INVESTIGATOR lat: 30.43826 lon: -84.28073 facility: START Treatment and Recovery Centers city: Brooklyn state: New York zip: 11238 country: United States name: Ana Ventuneac role: PRINCIPAL_INVESTIGATOR lat: 40.6501 lon: -73.94958 facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06307327 id: NFEC-2024-098 briefTitle: Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis overallStatus: RECRUITING date: 2024-03 date: 2025-12 date: 2026-12 date: 2024-03-12 date: 2024-03-26 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: Radiation oropharyngeal mucositis is one of the most painful side effects of radiotherapy in patients with head and neck tumors. However, the traditional radioactive oropharyngeal mucositis grading system has the problem of poor evaluation consistency. To solve this problem, we innovatively classify radiation oropharyngeal mucositis into four types according to the four-stage histopathological changes of acute radiation injury: (1) congestive; (2) Scattered erosion type; (3) Fusion erosion type; (4) Ulcer type. We intend to conduct a multicenter observational cohort study to compare the consistency of different physicians in the assessment of radiation oropharyngeal mucositis with new and traditional classifications, and to explore changes in blood markers of different types of oropharyngeal mucositis using clinical residual blood samples. conditions: Head and Neck Cancer conditions: Radiation-Induced Mucositis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 894 type: ESTIMATED measure: Evaluation consistency sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Southern medical university status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Jian Guan, M.D role: CONTACT phone: 86+13632102247 email: guanjian5461@163.com lat: 23.11667 lon: 113.25 facility: Huizhou Central People's Hospital status: NOT_YET_RECRUITING city: Huizhou state: Guangdong zip: 516000 country: China name: Yunming Tian role: CONTACT lat: 23.11147 lon: 114.41523 facility: Jieyang people's hospital status: NOT_YET_RECRUITING city: Jieyang state: Guangdong zip: 522000 country: China name: Peibao Lai role: CONTACT phone: 86+15975196057 email: boa71@139.com lat: 23.5418 lon: 116.36581 facility: Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou status: NOT_YET_RECRUITING city: Meizhou state: Guangdong zip: 514000 country: China name: Jianda Sun role: CONTACT lat: 24.2886 lon: 116.11767 hasResults: False
nctId: NCT06307314 id: NFEC-2024-093 briefTitle: Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis overallStatus: RECRUITING date: 2024-02-01 date: 2026-12-01 date: 2026-12-31 date: 2024-03-12 date: 2024-03-12 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year. At present, radiotherapy is an important measure to control the recurrence of head and neck tumors, but almost all patients with head and neck squamous cell carcinoma will have acute inflammatory reactions such as radiotherapy-induced oral mucositis (RIOM) after radiotherapy, which seriously affects the quality of life and radiotherapy efficacy of patients. Serum amyloid A1 (SAA1) is an acute phase protein associated with inflammation. Our previous basic research found that serum SAA1 expression levels can be used as biomarkers to assess the dose received by the receptor in the early stages of radiation damage. At the same time, we confirmed that the serum level of SAA1 in patients with nasopharyngeal carcinoma increased after radiotherapy. Therefore, we intend to conduct a prospective, multicenter, observational study to further explore the predictive power of plasma SAA1 levels for radiotherapy-induced oral mucositis, with a view to early screening and prevention of RIOM patients. conditions: Nasopharyngeal Carcinoma conditions: Head and Neck Cancer conditions: Radiotherapy-induced Oral Mucositis conditions: Biomarker studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: Different grades radiotherapy-induced oral mucositis measure: Start and duration of radiotherapy-induced oral mucositis measure: Side effects of radiotherapy measure: Tumor response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang hospital, Southern medical university status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Jian Guan, Ph.D. role: CONTACT lat: 23.11667 lon: 113.25 facility: Fujian Provinical Hospital status: NOT_YET_RECRUITING city: Fuzhou country: China name: Yongmei Dai role: CONTACT lat: 26.06139 lon: 119.30611 facility: Huizhou Central People's Hospital status: NOT_YET_RECRUITING city: Huizhou country: China name: Yunming Tian role: CONTACT lat: 23.11147 lon: 114.41523 facility: Jieyang People's Hospital status: NOT_YET_RECRUITING city: Jieyang country: China name: Peibao Lai role: CONTACT lat: 23.5418 lon: 116.36581 facility: Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou status: NOT_YET_RECRUITING city: Meizhou country: China name: Jianda Sun role: CONTACT lat: 24.2886 lon: 116.11767 hasResults: False
nctId: NCT06307301 id: PRO00031998 briefTitle: Study in ALS With Abatacept & IL-2 overallStatus: ACTIVE_NOT_RECRUITING date: 2021-10-28 date: 2024-10-17 date: 2024-10-17 date: 2024-03-12 date: 2024-04-16 name: The Methodist Hospital Research Institute class: OTHER briefSummary: In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T-lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. The investigator completed a phase 1 study of infusions of expanded autologous Tregs in combination with subcutaneous IL-2 injections in ALS patients, which showed enhancement of Treg numbers and suppressive function in vivo. The enhanced Treg suppressive function correlated strongly with slowing and stabilization of disease progression. Drugs that enhance endogenous Treg numbers and suppressive function may also stabilize disease in ALS. This phase 1 study aims to determine whether the combination therapy of subcutaneous IL-2 and abatacept (Orencia®) is safe and well-tolerated in 6 patients with ALS, and whether the therapy enhances Treg numbers and suppressive function in vivo. conditions: Amyotrophic Lateral Sclerosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 5 type: ACTUAL name: Abatacept Injection [Orencia] and Proleukin (aldesleukin) measure: To evaluate adverse events and laboratory abnormalities to assess the safety and tolerability of abatacept followed by Interleukin 2 (IL-2) administration in ALS patients measure: Change in Regulatory T cells (Tregs) numbers in the blood from baseline measure: Change in Regulatory T cells (Tregs) suppressive function in the blood from baseline measure: Changes in the level of cytokines secreted by PBMCs from baseline measure: Changes in Appel Amyotrophic Lateral Sclerosis rating scale ( AALS) slope measure: Changes in Amyotrophic Lateral Sclerosis functional rating scale-revised (ALSFRS-R) slope measure: Changes in forced vital capacity (FVC) and maximum inspiratory pressure (MIP) scores measure: Changes in maximum inspiratory pressure (MIP) scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Houston Methodist Research Institute city: Houston state: Texas zip: 77030 country: United States lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06307288 id: 20240301-2 briefTitle: Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea overallStatus: ENROLLING_BY_INVITATION date: 2023-10-16 date: 2024-06-01 date: 2024-06-01 date: 2024-03-12 date: 2024-03-12 name: Second Affiliated Hospital of Xi'an Jiaotong University class: OTHER briefSummary: Rosacea is a chronic inflammatory skin disease with a complex pathogenesis involving multiple factors. Currently, the treatment of rosacea remains highly challenging. Mast cells, as key participants in the pathogenesis of rosacea, have been shown to alleviate rosacea symptoms with some topical, oral, and injectable mast cell stabilizers in recent years. Tranilast stabilizes mast cells and basophils by acting on their cell membranes and preventing their degranulation. Tranilast has been used in the treatment of various skin disease, such as hypertrophic scars and atopic dermatitis. Minocycline is a first-line treatment for rosacea, and low-dose minocycline treatment (50mg/day) is believed to have anti-inflammatory effects without antibacterial effects, thus minimizing the dysbiosis and bacterial resistance caused by antibiotic use. Therefore, this study aims to investigate the effectiveness and safety of combining mast cell stabilizer tranilast with low-dose minocycline treatment for rosacea, providing new treatment options and insights for rosacea patients. conditions: Rosacea studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: minocycline name: tranilast measure: lesion counts measure: Clinician's Erythema Assessment score measure: Global Flushing Severity Scale score measure: Global Acne Grading System score measure: patient satisfaction evaluation measure: melanin index measure: erythema index measure: transepidermal water loss measure: Dermatology Life Quality Index score sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: The Second Affiliated Hospital of Xi'an Jiaotong Universi city: Xi'an state: Shaanxi zip: 710000 country: China lat: 34.25833 lon: 108.92861 hasResults: False